Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
| 0.0003 | |
| 0.0003 | |
| - | |
| 0.0003 | |
| 0.0003 | |
| 0.0003-0.81 | |
| 16 355 | |
| 54 516 K | |
| 0 | |
| -0.15 | |
| 2.049 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
In October 2021, I made a big call on Longeveron (NASDAQ:LGVN) stock, a biotech firm working on a promising Alzheimer’s therapy. Within six weeks, shares had risen over 11x… a stunning 1,000% ret...
Like the tempting Google search engine option, if you’re feeling lucky, you may want to try your hand at some penny stocks which possibly feature strong upside catalysts. Just to get everyone on the...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
